Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Alder BioPharmaceuticals Merges with H. Lundbeck in $1.95 Billion Deal
H. Lundbeck A/S (OMX: LUN), the specialty pharmaceutical giant based in Denmark, announced its first acquisition in over a year. The company revealed it was buying Alder BioPharmaceuticals (NASDAQ: ALDR), a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. One product candidate is ALD1910, a monoclonal antibody for migraine prevention. Lundbeck gains Alder’s eptinezumab product, an investigational monoclonal antibody for migraine prevention that it will develop and launch worldwide in the upcoming years. Lundbeck expects to see significant growth in its brain... Read More »
EyeCare Partners Grows Its National Platform
EyeCare Partners’ acquisition marathon shows no signs of slowing down. Ever since FFL Partners formed the group with the acquisition of Clarkson Eyecare in April 2015, EyeCare Partners (ECP) has expanded rapidly, consolidating smaller firms to grow a national network. Last week, the group purchased Nationwide Vision from Refac Optical Group, a portfolio company of Acon Investments. Nationwide is a full-service vision care provider operating 89 optometry offices throughout Arizona and Florida. This acquisition brings EyeCare Partners’ network range to up to 450 locations nationwide. No financial terms were disclosed. Earlier in September, ECP acquired Associated Retinal... Read More »
Health Care M&A Deals, Week Ending September 20, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price H. Lundbeck A/S Alder BioPharmaceuticals $1,950,000,000 eHealth Acquirer Target Price HMS Holdings Corp. VitreosHealth $36,500,000 Labs, MRI & Dialysis Acquirer Target Price Praesidian Capital Genetics business Long-Term Care... Read More »
OptimizeRx Grows Patient Communication Platform with RMDY Acquisition
OptimizeRx (NYSE: OPRX), a digital patient communication company, ramped up its platform last week with the acquisition of RMDY Health for $16 million. RMDY offers a SaaS platform that provides a complete digital framework to help life science and healthcare stakeholders design and launch their own white-label collaborative digital care and patient support programs. The company’s web and mobile platform supports a wide range of digital therapeutic initiatives, with a focus on care and chronic disease management, among others. For 2019, the company has an estimated annual revenue of $3 million. The acquisition adds three new client segments to OptimizeRx’s existing patient... Read More »
Health Care M&A Deals, Week Ending September 13, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Generex Biotechnology Corporation ALTuCELL, Inc. N/A Alexion Pharmaceuticals, Inc. Exclusive license to AG10 $50,000,000 Flexion Therapeutics, Inc. Rights to XEN402 $3,000,000 GlaxoSmithKline plc Sitari Pharmaceuticals N/A eHealth Acquirer Target... Read More »
IPA Group Acquired by Apollo Medical Holdings
Apollo Medical Holdings, Inc. (OTCQB: AMEH), an integrated population health management company, announced a new acquisition last week. The group acquired Accountable Health Care for $7.25 million, an independent practice association (IPA) that operates a network with more than 450 primary and 700 specialty care physicians. They provide healthcare services to more than 91,000 members of federally qualified health plans and multiple product lines. Apollo Medical is acquiring the group through its affiliates, Allied Pacific of California and APC-LSMA Designated Shareholder Medical Corporation (APC-LSMA). APC-LSMA will own 75% and Allied Pacific of California will own 25% of all outstanding... Read More »
Managed Care Deals for All in 2019
Investors seem unfazed by the Democratic presidential candidates’ debate around the topic of “Medicare for All.” Mergers and acquisitions in the Managed Care sector are flowing quite well this year. Halfway through September, 20 deals have been announced, putting this sector on track to equal or possibly exceed the 25 deals announced in 2018. Over the last decade, annual deal volume in this sector has averaged 20 deals per year. The peak was hit in 2015 with 43 deals, not including the terminated mega-deals between Aetna and Humana (NYSE: HUM) for $37 billion and Anthem (NYSE: ANTM) and Cigna (NYSE: CI) for $54 billion. In June of that year the U.S. Supreme Court ruled... Read More »
Baxter International Catches Cheetah Medical
Baxter International (NYSE: BAX) has been quiet on the merger and acquisition front since January 2018. The deal drought ended on September 10, 2019 when the med-tech company announced its acquisition of Cheetah Medical, based in Newton Center, Massachusetts. Cheetah provides non-invasive fluid management monitoring technologies, designed for use in critical care, operating room and emergency department settings. Its technology is available in approximately 30 countries. The price for the privately held company was $190 million in cash upfront and an additional $40 million in clinical and commercial milestones. This acquisition boosts Baxter’s portfolio with a non-invasive... Read More »
August Deal Flow Ebbs, as It Follows the Annual Cycle
Enough about slowdowns and recession. August is typically a roller-coaster month in the equity markets and August 2019 didn’t disappoint in that regard. The bond markets’ inverted yield curve persisted into September and that’s never a good sign. We’re moving on. Preliminary data show August’s deal volume wasn’t so bad, considering how most of 2019 has played out. The 125 deals announced in August represent a drop of 8% compared with the previous month’s 136 deals, and a 27% drop compared with August 2018. After a record-setting year in 2018, with more than 1,900 transactions and $333.3 billion on the books, a repeat would be nearly as scary as a sudden downturn (which may be coming,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
